, Virology of hepatitis D virus, Semin Liver Dis, vol.32, pp.195-200, 2012.
, influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. the european concerted action on viral hepatitis (eurohep), Gut, vol.46, pp.420-426, 2000.
, Hepatitis delta virus, The Lancet, vol.378, pp.73-85, 2011.
, rizzetto M. investigational drugs in development for Hepatitis D, vol.26, pp.999-1005, 2017.
, Sureau c, negro F. the hepatitis delta virus: replication and pathogenesis, J Hepatol, vol.64, pp.102-118, 2016.
, Kinetic parameters of trans scission by extended hdv-like ribozymes and the prospect for the discovery of genomic trans-cleaving rnas, Biochemistry, vol.57, pp.1440-50, 2018.
, a targeted functional rna interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses, Hepatology, vol.63, pp.35-48, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01796197
, Hepatitis B virus receptors and molecular drug targets, Hepatol Int, vol.10, pp.567-73, 2016.
, Host-targeting agents for treatment of hepatitis B virus infection, Curr Opin Virol, vol.14, pp.41-47, 2015.
, Baumert tF. targeting viral entry for treatment of Hepatitis B and c virus infections, ACS Infect Dis, vol.1, pp.420-427, 2015.
, tuning a cellular lipid kinase activity adapts hepatitis c virus to replication in cell culture, Nat Microbiol, vol.2, p.16247, 2016.
, clearance of persistent hepatitis c virus infection in humanized mice using a claudin-1-targeting monoclonal antibody, Nat Biotechnol, vol.33, pp.549-54, 2015.
, Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2a trial, Lancet Infect Dis, vol.15, pp.1167-74, 2015.
, treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase ib/iia study, J Hepatol, vol.65, pp.490-498, 2016.
, ng a, et al. a genome-wide genetic screen for host factors required for hepatitis c virus propagation, Proc Natl Acad Sci U S A, vol.106, pp.16410-16415, 2009.
, identification of host proteins required for HiV infection through a functional genomic screen, Science, vol.319, pp.921-927, 2008.
, Kusche-gullberg M. the exostosin family: proteins with many functions, Matrix Biol, vol.35, pp.25-33, 2014.
, rpb4 and rpb7: multifunctional subunits of rna polymerase ii, Crit Rev Microbiol, vol.39, pp.362-72, 2013.
, rna polymerase ii subunit rPB9 is required for accurate start site selection, Genes Dev, vol.9, pp.481-90, 1995.
, Hypoxia-inducible factor-1? plays roles in epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZlF1 gene promoter, PLoS Pathog, vol.13, p.1006404, 2017.
, Hypoxia inducible factor one alpha and human viral pathogens, Curr Res Transl Med, vol.65, pp.7-9, 2017.
, Hypoxia inducible factor HiF-1 promotes myeloidderived suppressor cells accumulation through entPD2/cD39l1 in hepatocellular carcinoma, Nat Commun, vol.8, p.517, 2017.
, the role of Hypoxia inducible Factor-1 in Hepatocellular carcinoma, Biomed Res Int, vol.2014, pp.1-11, 2014.
, on October 15, 2019 at INSERM Consortia. Protected by copyright, 2019.
, Gut, vol.0, pp.1-10, 2019.
, Hepatology
, Hypoxia inducible factor in hepatocellular carcinoma: a therapeutic target, World J Gastroenterol, vol.21, pp.12171-12179, 2015.
, Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway, J Biol Chem, vol.279, pp.33035-33043, 2004.
, Pyrimidine pathways in health and disease, Trends Mol Med, vol.11, pp.430-437, 2005.
, effects of flanking regions on HDV cotranscriptional folding kinetics, RNA, vol.24, pp.1229-1269, 2018.
, Stark gr. n-(phosphonacetyl)-l-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture, J Biol Chem, vol.249, pp.6945-50, 1974.
, inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity, PLoS Pathog, vol.9, p.1003678, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01113535
, ribavirin: recent insights into antiviral mechanisms of action, Curr Opin Drug Discov Devel, vol.4, pp.651-657, 2001.
, Management of adverse effects of Peg-iFn and ribavirin therapy for hepatitis c, Nat Rev Gastroenterol Hepatol, vol.8, pp.212-235, 2011.
, nelfinavir: a review of its use in the management of HiV infection, Drugs, vol.65, pp.2209-2253, 2005.
, De angelis c, et al. eSr1 mutations-a mechanism for acquired endocrine resistance in breast cancer, Nat Rev Clin Oncol, vol.12, pp.573-83, 2015.
, estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients, Breast Cancer Res Treat, vol.82, pp.103-114, 2003.
, Uridine and its nucleotides: biological actions, therapeutic potentials, Trends Pharmacol Sci, vol.20, pp.218-243, 1999.
, Oligomeric structure of the multifunctional protein caD that initiates pyrimidine biosynthesis in mammalian cells, Proc Natl Acad Sci U S A, vol.82, pp.6802-6808, 1985.
, Parallel shrna and criSPr-cas9 screens enable antiviral drug target identification, Nat Chem Biol, vol.12, pp.361-367, 2016.
, elegans pharyngeal morphogenesis requires both de novo synthesis of pyrimidines and synthesis of heparan sulfate proteoglycans, Dev Biol, vol.296, pp.409-429, 2006.
, the estrogen receptor ?-cistrome beyond breast cancer, Mol Endocrinol, vol.30, pp.1046-58, 2016.
, ribavirin: past, present and future, World J Hepatol, vol.8, pp.123-153, 2016.
, ribavirin inhibits in vitro hepatitis e virus replication through depletion of cellular gtP pools and is moderately synergistic with alpha interferon, Antimicrob Agents Chemother, vol.58, pp.267-73, 2014.
, HBV cure: why, how, when?, Curr Opin Virol, vol.18, pp.135-178, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01797257
, clinical development of hepatitis c virus host-targeting agents, Lancet, vol.389, pp.674-679, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01910174
, Safety, tolerability, and antiviral effect of rg-101 in patients with chronic hepatitis c: a phase 1B, double-blind, randomised controlled trial, Lancet, vol.389, pp.709-726, 2017.
, leflunomide: a promising drug with good antitumor potential, Biochem Biophys Res Commun, vol.496, pp.726-756, 2018.
, teriflunomide and its mechanism of action in multiple sclerosis, Drugs, vol.74, pp.659-74, 2014.
, Dihydroorotate dehydrogenase inhibitor a771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells, Mol Cancer Ther, vol.8, pp.366-75, 2009.
, egFr and epha2 are host factors for hepatitis c virus entry and possible targets for antiviral therapy, Nat Med, vol.17, pp.589-95, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00705829
, Hepatitis B virus evasion from cyclic guanosine monophosphate-adenosine monophosphate synthase sensing in human Hepatocytes, Hepatology, vol.68, pp.1695-709, 2018.
, Solute carrier ntcP regulates innate antiviral immune responses targeting Hepatitis c virus infection of hepatocytes, Cell Rep, vol.17, pp.1357-68, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01911211
, on October 15, 2019 at INSERM Consortia. Protected by copyright, 2019.